SEC Form SC 13G/A filed by Palisade Bio Inc. (Amendment)

$PALI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $PALI alert in real time by email
SC 13G/A 1 ea192887-13ga2intra_palisade.htm AMENDMENT NO. 2 TO SCHEDULE 13G

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

 

(Amendment No. 2)*

 

Palisade Bio, Inc.

 

(Name of Issuer)

 

Common Stock, $0.01 par value per share

 

(Title of Class of Securities)

 

696389204

 

(CUSIP Number)

 

December 31, 2023

 

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

a. Rule 13d-1(b)

 

b. Rule 13d-1(c)

 

c. Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

Page 1 of 6

 

 

CUSIP No. 696389204
 

 

   
1. Names of Reporting Persons.
   
 

Mitchell P. Kopin

   
   
2. Check the Appropriate Box if a Member of a Group (See Instructions)
   
  (a)    ☐
  (b)    ☐
   
   
3. SEC Use Only
   
   
4. Citizenship or Place of Organization     United States of America
   

 

Number of
Shares Beneficially
Owned by Each
Reporting Person
With:
5.  Sole Voting Power 0
   
   
6.  Shared Voting Power

180,532

   
   
7.  Sole Dispositive Power 0
   
   
8.  Shared Dispositive Power

180,532

 

   
9. Aggregate Amount Beneficially Owned by Each Reporting Person     180,532 (see Item 4)
   
   
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ☐
   
   
11. Percent of Class Represented by Amount in Row (9)    1.9% (see Item 4)
   
   
12. Type of Reporting Person (See Instructions)
   
  IN; HC

 

Page 2 of 6

 

 

CUSIP No. 696389204
 

 

   
1. Names of Reporting Persons.
   
 

Daniel B. Asher

   
   
2. Check the Appropriate Box if a Member of a Group (See Instructions)
   
  (a)    ☐
  (b)    ☐
   
   
3. SEC Use Only
   
   
4. Citizenship or Place of Organization     United States of America
   

 

Number of
Shares Beneficially
Owned by Each
Reporting Person
With:
5.  Sole Voting Power 0
   
   
6.  Shared Voting Power

180,532

   
   
7.  Sole Dispositive Power 0
   
   
8.  Shared Dispositive Power

180,532

 

   
9. Aggregate Amount Beneficially Owned by Each Reporting Person     180,532 (see Item 4)
   
   
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ☐
   
   
11. Percent of Class Represented by Amount in Row (9)    1.9% (see Item 4)
   
   
12. Type of Reporting Person (See Instructions)
   
  IN; HC

  

Page 3 of 6

 

 

CUSIP No. 696389204
 

 

   
1. Names of Reporting Persons.
   
 

Intracoastal Capital LLC

   
   
2. Check the Appropriate Box if a Member of a Group (See Instructions)
   
  (a)    ☐
  (b)    ☐
   
   
3. SEC Use Only
   
   
4. Citizenship or Place of Organization     Delaware
   

 

Number of
Shares Beneficially
Owned by Each
Reporting Person
With:
5.  Sole Voting Power 0
   
   
6.  Shared Voting Power

180,532

   
   
7.  Sole Dispositive Power 0
   
   
8.  Shared Dispositive Power

180,532

 

   
9. Aggregate Amount Beneficially Owned by Each Reporting Person     180,532 (see Item 4)
   
   
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ☐
   
   
11. Percent of Class Represented by Amount in Row (9)    1.9% (see Item 4)
   
   
12. Type of Reporting Person (See Instructions)
   
  OO

  

Page 4 of 6

 

 

This Amendment No. 2 is being filed jointly by the Reporting Persons and amends the Schedule 13G initially filed by the Reporting Persons with the Securities and Exchange Commission (the “SEC”) on August 22, 2022, as amended by Amendment No. 1 thereto filed by the Reporting Persons with the SEC on February 8, 2023 (the “Schedule 13G”).

 

Except as set forth below, all Items of the Schedule 13G remain unchanged. All capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13G.

 

Item 4. Ownership.

 

(a) and (b):

 

As of close of business on December 31, 2023, each of the Reporting Persons may have been deemed to have beneficial ownership of 180,532 shares of Common Stock, which consisted of (i) 3,086 shares of Common Stock issuable upon an exercise of a warrant held by Intracoastal (“Intracoastal Warrant 1”), (ii) 64,000 shares of Common Stock issuable upon an exercise of a second warrant held by Intracoastal (“Intracoastal Warrant 2”) and (iii) 113,446 shares of Common Stock issuable upon an exercise of a third warrant held by Intracoastal (“Intracoastal Warrant 3”), and all such shares of Common Stock in the aggregate represented beneficial ownership of approximately 1.9% of the Common Stock, based on (1) 9,270,894 shares of Common Stock outstanding as of December 28, 2023, as reported by the Issuer, (2) 3,086 shares of Common Stock issuable upon an exercise of Intracoastal Warrant 1, (3) 64,000 shares of Common Stock issuable upon an exercise of Intracoastal Warrant 2 and (4) 113,446 shares of Common Stock issuable upon an exercise of Intracoastal Warrant 3.

 

(c) Number of shares as to which each Reporting Person has:

 

(i) Sole power to vote or to direct the vote:       0      .

 

(ii) Shared power to vote or to direct the vote:      180,532     .

 

(iii) Sole power to dispose or to direct the disposition of      0     .

 

(iv) Shared power to dispose or to direct the disposition of      180,532     .

 

Item 5. Ownership of Five Percent or Less of a Class

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ.

 

Item 10. Certification

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
 

Page 5 of 6

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: February 6, 2024

 

  /s/ Mitchell P. Kopin
  Mitchell P. Kopin
   
  /s/ Daniel B. Asher
  Daniel B. Asher

 

  Intracoastal Capital LLC
     
  By: /s/ Mitchell P. Kopin
    Mitchell P. Kopin, Manager

 

Page 6 of 6

 

 

 

Get the next $PALI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PALI

DatePrice TargetRatingAnalyst
2/2/2022$5.00Buy
Ladenburg Thalmann
8/31/2021$7.00Buy
Maxim Group
More analyst ratings

$PALI
Press Releases

Fastest customizable press release news feed in the world

See more
  • Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

    Positive preliminary data from all five single ascending dose (SAD) cohorts and first three completed multiple ascending dose (MAD) cohorts support safety and tolerability of PALI-2108 No serious adverse events (SAEs) and no treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs seen to date On track to report topline data in first half of 2025 Carlsbad, CA, March 14, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today provided an upda

    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

    PALI-2108, a Colon-Specific PDE4 Inhibitor Prodrug, Abstract was Rated in the Top 10% of all AGA Abstracts Selected for Poster Presentation at DDW Carlsbad, CA, March 12, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it has been selected to present data from its lead program PALI-2108 for the treatment of ulcerative colitis at Digestive Disease Week® (DDW) 2025 being held May 3–6, in San Diego, California. Participation details are as foll

    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Palisade Bio Participates in Virtual Investor "What This Means" Segment

    Dr. Joerg Heyer, Head of Translational Science and Medicine of Palisade Bio highlights preclinical data for lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) Carlsbad, CA, March 04, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the release of a Virtual Investor "What This Means" segment. As part of this segment, Dr. Heyer discussed the Company's positive preclinical data for its lead product candidate, PALI-2108, w

    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$PALI
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PALI
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$PALI
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PALI
SEC Filings

See more

$PALI
Leadership Updates

Live Leadership Updates

See more
  • Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

    Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) --  Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases, today announced the appointment of Brian G. Feagan, MD, FRCPC, to its Clinical Advisory Board. Dr. Feagan is a distinguished gastroenterologist with over 30 years of experience in the design, conduct, and execution of large-scale randomized controlled trials (RCTs) for Crohn's disease (CD) and ulcerative colitis (UC). He has served as Principal Investigator in more than 140 multi-center RCTs and has dedicated mu

    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Palisade Bio Appoints Margery Fischbein to its Board of Directors

    Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has appointed Margery Fischbein to its Board of Directors. Ms. Fischbein is a highly experienced healthcare investment banker and accomplished biotechnology industry executive. "We are excited to welcome Ma

    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Correction Notice of Palisade Bio's Press Release Announcing the Appointment of Clinical Advisory Board Members

    Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (NASDAQ:PALI) ("Palisade" or the "Company"), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced a correction to its press release originally issued on February 8, 2024, announcing the appointments of Bruce Sands, MD, MS and Florian Rieder, MD to its Clinical Advisory Board (CAB). In the original press release, it was incorrectly stated that the PALI-2108 development program was on track to commence a Phase 1 clinical study next year. The Company reiterates its guidance that the PALI-2108 Phase 1 clinical study is on track to launch in 20

    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$PALI
Financials

Live finance-specific insights

See more
  • Palisade Bio (Nasdaq: PALI) Announces Analysis Demonstrating LB1148 Reduced the Extent and Severity of Post-Surgical Intraabdominal Adhesions by 93%

    Data from Pooled-Analysis of Enteral Protease Inhibitor LB1148 Demonstrated 72% Reduction in the Risk of Adhesion Formation in Patients Undergoing Bowel Resection Surgery Company to Host Conference Call on Wednesday, March 16, 2022, at 8:30 a.m. EDT CARLSBAD, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced data from a Pooled-Analysis of Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN.) These data are featured today at the Next Big Thing session of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 202

    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$PALI
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more